ABBV - Abbvie Inc
Close
196.31
1.130 0.576%
Share volume: 3,819,287
Last Updated: Fri 30 Aug 2024 10:00:03 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$195.18
1.13
0.58%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-04 | 2022-11-04 | 2023-02-17 | 2023-05-05 | 2023-08-07 | 2023-11-06 | 2024-02-20 | 2024-05-03 | |
Total revenue | 14.583 B | 14.812 B | 15.121 B | 12.225 B | 13.865 B | 13.927 B | 14.301 B | 12.310 B | |
Cost of revenue | 4.170 B | 5.022 B | 4.170 B | 3.986 B | 4.240 B | 6.485 B | 5.704 B | 4.094 B | |
Gross profit | 10.413 B | 9.790 B | 10.951 B | 8.239 B | 9.625 B | 7.442 B | 8.597 B | 8.216 B | |
-5.98% | 11.86% | -24.76% | 16.82% | -22.68% | 15.52% | -4.43% | |||
Operating expenses | 7.021 B | 4.918 B | 5.207 B | 5.331 B | 5.001 B | 5.095 B | 5.120 B | 5.254 B | |
Selling general and admin | 5.412 B | 3.304 B | 3.417 B | 3.039 B | 3.268 B | 3.372 B | 3.193 B | 3.315 B | |
Research and development | 1.609 B | 1.614 B | 1.790 B | 2.292 B | 1.733 B | 1.723 B | 1.927 B | 1.939 B | |
Total expenses | 11.191 B | 9.940 B | 9.377 B | 9.317 B | 9.241 B | 11.580 B | 10.824 B | 9.348 B | |
-11.18% | -5.66% | -0.64% | -0.82% | 25.31% | -6.53% | -13.64% | |||
Operating income | 3.392 B | 4.872 B | 5.744 B | 2.908 B | 4.624 B | 2.347 B | 3.477 B | 2.962 B | |
Ebit | 3.392 B | 4.872 B | 5.744 B | 2.908 B | 4.624 B | 2.347 B | 3.477 B | 2.962 B | |
Pretax income | 1.183 B | 4.400 B | 2.965 B | 475.000 M | 2.610 B | 1.953 B | 1.212 B | 1.755 B | |
271.94% | -32.61% | -83.98% | 449.47% | -25.17% | -37.94% | 44.80% | |||
Income tax | 255.000 M | 448.000 M | 493.000 M | 234.000 M | 583.000 M | 172.000 M | 388.000 M | 383.000 M | |
Net income basic | 913.000 M | 3.931 B | 2.470 B | 228.000 M | 2.013 B | 1.767 B | 812.000 M | 1.359 B | |
330.56% | -37.17% | -90.77% | 782.89% | -12.22% | -54.05% | 67.36% | |||
Net income | 913.000 M | 3.931 B | 2.470 B | 228.000 M | 2.013 B | 1.767 B | 812.000 M | 1.359 B | |
330.56% | -37.17% | -90.77% | 782.89% | -12.22% | -54.05% | 67.36% |